AbbVie Resultados de beneficios anteriores

Pasado controles de criterios 1/6

AbbVie ha aumentado sus beneficios a una tasa media anual de 11.5%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento de 12.7% anual. Los ingresos han ido creciendo a una tasa media de 13.2% al año. La rentabilidad financiera de AbbVie es de 46.9%, y sus márgenes netos son de 8.9%.

Información clave

8.8%

Tasa de crecimiento de los beneficios

5.1%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	12.0%
Rentabilidad financiera	57.7%
Margen neto	10.9%
Última actualización de beneficios	31 Mar 2024

Actualizaciones de resultados anteriores recientes

Recent updates

AbbVie Q4 Earnings Preview: Few Clouds On Horizon Thanks To Masterful Management (Rating Upgrade)

Jan 30

AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.55

Jan 05

AbbVie: Time To Lock In Gains (Rating Downgrade)

Jan 03

AbbVie Vs. GSK: Dual Dominance In Pharma

Dec 23

AbbVie's (NYSE:ABBV) Upcoming Dividend Will Be Larger Than Last Year's

Dec 12

4.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024

Nov 29

AbbVie (NYSE:ABBV) Has Announced That It Will Be Increasing Its Dividend To $1.55

Nov 28

AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks

Nov 21

AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.55

Oct 30

AbbVie Stock Still A Hold Despite Positive Third Quarter 2023 Results

Oct 30

AbbVie Q3 Earnings Preview: Tough Comparison For Humira Shouldn't Derail Growth Plans

Oct 23

AbbVie: Successfully Navigating Humira's Patent Cliff With 4% Yield And 270% DGR Since 2014

Oct 16

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero AbbVie. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NYSE:ABBV Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Mar 24	54,403	5,950	12,944	7,189
31 Dec 23	54,318	4,820	12,904	7,038
30 Sep 23	55,138	6,471	12,453	6,897
30 Jun 23	56,023	8,635	12,260	6,785
31 Mar 23	56,741	7,542	12,001	7,291
31 Dec 22	58,054	11,782	12,084	6,487
30 Sep 22	57,819	13,343	12,116	6,518
30 Jun 22	57,349	12,569	11,988	6,551
31 Mar 22	56,725	12,407	11,943	6,692
31 Dec 21	56,197	11,468	11,872	6,820
30 Sep 21	55,169	7,465	11,054	6,829
30 Jun 21	53,729	6,599	10,860	6,761
31 Mar 21	50,195	5,092	10,955	6,418
31 Dec 20	45,804	4,556	9,867	6,003
30 Sep 20	40,650	7,324	9,429	5,902
30 Jun 20	36,227	6,906	8,288	5,582
31 Mar 20	34,057	8,395	6,760	5,467
31 Dec 19	33,266	7,842	6,763	5,377
30 Sep 19	32,867	3,232	6,487	5,260
30 Jun 19	32,624	4,093	6,765	5,273
31 Mar 19	32,647	5,333	6,873	5,304
31 Dec 18	32,753	5,657	7,353	5,259
30 Sep 18	32,187	7,531	6,972	5,242
30 Jun 18	30,946	6,419	6,623	5,202
31 Mar 18	29,612	6,352	6,303	5,109
31 Dec 17	28,216	5,283	6,248	5,007
30 Sep 17	27,273	6,615	5,958	4,789
30 Jun 17	26,710	6,582	5,799	4,667
31 Mar 17	26,218	6,278	5,861	4,562
31 Dec 16	25,638	5,923	5,837	4,385
30 Sep 16	25,242	6,048	5,733	4,178
30 Jun 16	24,754	5,690	5,724	4,472
31 Mar 16	23,777	5,448	5,646	4,236
31 Dec 15	22,859	5,118	5,663	4,101
30 Sep 15	21,911	2,790	6,059	3,978
30 Jun 15	20,986	2,064	6,178	3,390
31 Mar 15	20,437	1,802	6,133	3,336
31 Dec 14	19,960	1,765	6,024	3,297
30 Sep 14	19,619	3,686	5,413	3,201
30 Jun 14	19,258	4,144	5,136	3,103
31 Mar 14	19,024	4,114	5,113	2,978
31 Dec 13	18,790	4,102	5,352	2,840
30 Sep 13	18,885	4,540	4,859	2,542
30 Jun 13	18,735	5,161	4,730	2,641

Ingresos de calidad: ABBV tiene un gran one-off loss de $9.8B impacto en sus últimos 12 meses de resultados financieros a 31st December, 2023.

Margen de beneficios creciente: Los actuales márgenes de beneficio(8.9%) de ABBV son inferiores a los del año pasado (20.3%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de ABBV han crecido un 11.5% al año en los últimos 5 años.

Acelerando crecimiento: ABBV ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: ABBV tuvo un crecimiento negativo de los beneficios (-59.1%) durante el año pasado, lo que dificulta la comparación con la media de la industria Biotechs (-8.9%).

Rentabilidad financiera

Alta ROE: Aunque la rentabilidad financiera (46.87%) de ABBV es excepcional, esta métrica está sesgada debido a su alto nivel de deuda.

AbbVie Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings: EPS misses analyst expectations

AbbVie Inc. Reports Unaudited Intangible Asset Impairment for the Quarter Ended December 31, 2023

AbbVie Inc. to Report Q4, 2023 Results on Feb 02, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

AbbVie's Q1: Positive Surprise

AbbVie Inc. Announces Positive Topline Results from Level Up

AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib (RINVOQ) Showed Positive Results in Patients with Giant Cell Arteritis

AbbVie: Great To Be Proven Wrong - Still Not A Buy

AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine

AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

Upcoming dividend of US$1.55 per share

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.

AbbVie Announces U.S. Food and Drug Administration Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

Executive VP & Chief Commercial Officer recently sold US$5.9m worth of stock

AbbVie Inc., Annual General Meeting, May 03, 2024

AbbVie: Strong Cash Flow Growth Fuels Dividend Growth

AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios

New minor risk - Insider selling

Chairman & CEO recently sold US$25m worth of stock

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Executive VP & COO notifies of intention to sell stock

Full year 2023 earnings: EPS misses analyst expectations

AbbVie Inc. Announces Chief Executive Officer Changes

Abbvie, Inc. Appoints Robert A. Michael as Member of the Board of Directors and Richard A. Gonzalez as Executive Chairman of the Board of Directors

Fourth quarter dividend of US$1.55 announced

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on May 15, 2024

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

Consensus EPS estimates fall by 13%

AbbVie's VYALEV™? (foslevodopa/Foscarbidopa Solution) Available for the Treatment of Advanced Parkinson's Disease in Canada

AbbVie: Things Are Getting Clearer

AbbVie Inc. Reports Unaudited Intangible Asset Impairment for the Quarter Ended December 31, 2023

AbbVie Q4 Earnings Preview: Few Clouds On Horizon Thanks To Masterful Management (Rating Upgrade)

AbbVie Inc. Launches Produodopa (Foslevodopa/Foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union

Abbvie Inc. Announces Phase 2 Results Showing Adults with Moderate to Severe Hidradenitis Suppurativa

AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.55

AbbVie Inc. to Report Q4, 2023 Results on Feb 02, 2024

Upcoming dividend of US$1.55 per share at 3.8% yield

AbbVie: Time To Lock In Gains (Rating Downgrade)

AbbVie Vs. GSK: Dual Dominance In Pharma

AbbVie's (NYSE:ABBV) Upcoming Dividend Will Be Larger Than Last Year's

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) for $8.2 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

AbbVie Inc. Announces Positive Topline Results from Phase 2 Luminosity Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer

4.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024

AbbVie Announces U.S. Food and Drug Administration and European Medicines Agency Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

AbbVie (NYSE:ABBV) Has Announced That It Will Be Increasing Its Dividend To $1.55

AbbVie Announces U.S. Food and Drug Administration and European Medicines Agency Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks

AbbVie Announces Results Evaluating the Efficacy, Safety, and Tolerability of UBRELVY

AbbVie (NYSE:ABBV) Will Pay A Larger Dividend Than Last Year At $1.55

AbbVie Stock Still A Hold Despite Positive Third Quarter 2023 Results

Abbvie Inc. Declares Quarterly Dividend, Payable on February 15, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Profit margin trend

Lupus Therapeutics Partners with AbbVie Inc. on Clinical Trial Recruitment Efforts in SLE Through Lucin Lupus Clinical Trial Network

AbbVie Q3 Earnings Preview: Tough Comparison For Humira Shouldn't Derail Growth Plans

Abbvie Inc. Epkinly™ (Epcoritamab Injection/Epcoritamab for Injection) Receives Health Canada Authorization with Conditions as the First and Only Subcutaneous Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl)

AbbVie: Successfully Navigating Humira's Patent Cliff With 4% Yield And 270% DGR Since 2014

AbbVie Presents Positive Results from Head-to-Head Phase 3 Sequence Study in Crohn's Disease Meets All Primary and Secondary Endpoints

AbbVie Inc. Announces Director Appointments

AbbVie Inc. Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (Upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Desglose de ingresos y gastos
Beta